Literature DB >> 4617861

[Letter: Crohn's disease and levamisole].

J Bertrand, G Renoux, M Renoux, A Palat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4617861

Source DB:  PubMed          Journal:  Nouv Presse Med        ISSN： 0301-1518


× No keyword cloud information.
  6 in total

Review 1.  Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.

Authors:  A B Hawthorne; C J Hawkey
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

2.  Pharmacokinetics of levamisole in healthy subjects and cancer patients.

Authors:  M Luyckx; F Rousseau; M Cazin; C Brunet; J C Cazin; J M Haguenoer; B Devulder; I Lesieur; D Lesieur; P Gosselin; L Adenis; P Cappelaere; A Demaille
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Oct-Dec       Impact factor: 2.441

3.  Inhibition of the E-rosette formation of T-lymphocytes by aggregated human IgG and restoration by levamisole.

Authors:  W De Cock; J De Cree; H Verhaegen
Journal:  Immunology       Date:  1978-08       Impact factor: 7.397

4.  Restoration by levamisole of low E-rosette forming cells in patients suffering from various diseases.

Authors:  H Verhaegen; J De Cree; W De Cock; F Verbruggen
Journal:  Clin Exp Immunol       Date:  1977-02       Impact factor: 4.330

5.  Controlled therapeutic trial of levamisole and sulphasalazine in acute ulcerative colitis.

Authors:  A Hermanowicz; A Nowak; L Gajos
Journal:  Gut       Date:  1984-05       Impact factor: 23.059

6.  [The immune competence of patients with Crohn's disease (author's transl)].

Authors:  E Tönnesmann; P A Bürkle; B Schäfer; K Federlin
Journal:  Klin Wochenschr       Date:  1979-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.